OncoHost, a Binyamina, Israel-based leader in host response profiling for improved personalized cancer therapy, completed an $8m Series B funding round.
The round was led by OurCrowd, joined by a group of family offices and private investors.
The funding will help finance the company’s ongoing clinical trials, open a US-based affiliate and prepare for the upcoming launch of PROphet®, its machine learning-based Host Response Profiling platform that combines proteomic analysis with AI to predict patient response to immunotherapy, providing clinicians with potential combination strategies to overcome treatment resistance.
Led by Ofer Sharon, MD, CEO, OncoHost is a clinical stage precision oncology startup, combining life-science research and advanced machine learning technology to develop personalized strategies for cancer patients. Clinical trials are currently focused on melanoma and non-small cell lung cancer (NSCLC) patients and will soon expand to other indications. Its platform, PROphet®, analyzes proteomic changes in patient blood samples to detect signs of resistance to cancer therapies in real-time, enabling biomarker-guided treatment planning for physicians, target discovery for drug development and, ultimately, improved outcomes for patients.
PROphet® will first be made available to healthcare providers who can use it to help assess how a specific patient may respond to a given treatment. This will aid the oncologist and patient in making informed decisions regarding treatment options, lines of therapy, potential combination treatments, and participation in clinical trials.
FinSMEs
20/01/2021